NCT06415279已完成4 期
Clinical Evaluation of the Sebum Reduction Induced by Clascoterone Cream 1%
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- The primary efficacy endpoint is the change in causal sebum measurements from the forehead obtained with a sebumeter during the study.
研究概览
简要总结
The etiology of acne is heavily dependent on the production of sebum by the sebaceous glands that results in the growth of the bacteria c. acnes. If no sebum is present, there is no nutritional source for the c. acnes, the bacteria die, and acne resolves. A newly FDA approved acne medication consisting of clascoterone cream 1% is believed to effectively treat acne due to a decrease in sebum production. This mechanism of action has been postulated based on efficacy observed in the phase III trials that lead to its approval. This research aims to demonstrate the effect of clascoterone cream 1% in sebum reduction.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males and females 12+ years of age.
- •Subjects with mild to moderate acne.
- •Subjects must possess 10-100 total non-inflammatory lesions (open comedones and closed comedones), 10-50 total inflammatory lesions, no cysts, and up to 2 nodules (if deemed appropriate by the PI) on the face.
- •Subjects with all Fitzpatrick skin types I-VI.
- •Subjects who agree to use only the study products for acne treatment. No other medicated cleansers or moisturizers or acne treatments of any kind are allowed.
- •Subjects agree not to introduce any new colored cosmetics or skin care products while participating in the study (lipsticks, eye shadows, facial foundations, blush, powder, cleansers, moisturizers).
- •Subjects agree to arrive at all visits with a clean face, having washed his/her face and removed all facial and eye makeup products within 2 hours to 4 hours prior to the visit and is not to use/apply any topical facial product(s) until the visit is completed.
- •No known medical conditions that, in the investigator's opinion, may interfere with study participation.
- •Women of childbearing potential must be willing to use a form of birth control during the study. For the purpose of this study, the following are considered acceptable methods of birth control: oral contraceptives, Norplant, Depo-Provera, double barrier methods (e.g., condom and spermicide) and abstinence.
- •Subjects are dependable and able to follow directions and willing to comply with the schedule of visits.
- •Subjects in generally good physical and mental health.
- •Able to read, write, speak, and understand English
- •Individual (and/or his/her legally acceptable representative, as applicable) has signed the Consent for Photograph Release and ICD (and/or Assent Document, as applicable) including Health Insurance Portability and Accountability Act (HIPAA) disclosure.
- •Subject must avoid sun exposure, or use sunscreen if sun exposure is unavoidable.
- •Subject must avoid professional or facial spa procedures during the study.
排除标准
- •Any dermatological disorder, which in the investigator's opinion, may interfere with the accurate evaluation of the subject's skin characteristics, except for the study condition of acne.
- •Subjects who are not willing to use the assigned study product to their face as instructed.
- •Subjects who have acne nodules/cysts representative of severe acne.
- •Subjects who are currently using, planning to use during the study or has used any of the following in the specified time range (based on subject report):
- •1 month prior to Visit 1: Prescription (oral or topically applied on the face) antibiotics, inhaled steroids (except those prescribed for allergies), or hormones (pre- or post-menopausal hormone-replacement therapy; insulin, etc.), or other medications that could make skin more sensitive or have an effect on the skin, as determined by the PI or designee. Oral contraceptives are acceptable.
- •1 month prior to Visit 1: Prescription medication for acne (e.g. doxycycline, minocycline, clindamycin, sulfamethoxazole and trimethoprim [Bactrim], tetracycline, erythromycin, azithromycin, or Vibramycin®)
- •1 month prior to Visit 1: Topical prescription retinoids (e.g. Retin-A®, Retin-A Micro®, Renova®, Adapalene, Tazarotene, Avita®, Tazorac®, Avage®, Differin®), azelaic acid, benzoyl peroxide, dapsone, sodium sulfacetamide, Epiduo®, or other similar prescription drug on the face
- •6 months prior to Visit 1: Accutane or other oral retinoid
- •2 weeks prior to Visit 1: Any of the following on the face:
- •Light therapy
- •OTC topical medications/products (including antiacne or antibacterial agents, topical anti-inflammatories, topical retinoids, etc.). Sunscreens (SPF) are acceptable.
- •Females who are pregnant, lactating, or planning to become pregnant during the study or within 30 days of study completion. (Subject must document her response in either the source documentation or informed consent/assent forms).
- •Subject has a surgery and/or invasive medical procedure planned during the study.
- •Subject has observable suntan, scars, nevi, tattoo, excessive hair (including beard, mustache, or goatee), or other dermal conditions on the face that that could interfere with study evaluations or confound study results, as determined by the PI or designee.
- •Subject is taking medications that would mask an adverse event (AE) or influence the study results, including:
- •Immunosuppressive drugs and steroidal and/or non-steroidal anti-inflammatory drugs within 3 months before Visit 1 and during the study.
- •Regular use of antihistamines within 1 month before Visit 1 and during the study.
- •Subject has a history of or a concurrent health condition/situation, which in the opinion of the PI, if medically qualified, or Study Physician, may put the individual at significant risk, confound the study results, or interfere significantly with the individual's participation in the study.
- •Subject is an employee/contractor or immediate family member of the PI, Study Site, or Sponsor.
- •Subjects with clinically significant unstable medical disorders.
- •Subjects who are unwilling or unable to comply with the requirements of the protocol.
- •Subjects with any known allergies or sensitivities to the study acne products.
- •Subjects who are currently under the care of a dermatologist for acne.
- •Subjects who are currently experiencing an acne flare.
- •Subjects who have history of a psychological illness or condition that would interfere with their ability to understand and follow the requirements of the study.
- •Subjects having started hormone replacement therapies (HRT) or hormones for birth control less than 3 months prior to the study entry or who plan on starting, stopping or changing doses of HRT or hormones for birth control during the study.
研究组 & 干预措施
Winlevi (clascoterone) 1% cream
Experimental
干预措施: Winlevi (clascoterone) 1% cream (Drug)
结局指标
主要结局
The primary efficacy endpoint is the change in causal sebum measurements from the forehead obtained with a sebumeter during the study.
时间窗: Weeks 16
次要结局
- The secondary efficacy endpoint is the changes in the facial microbiome induced by 8, 12, and 52 weeks of clascoterone 1% cream application.(Weeks 52)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Decreasing Severity of Acne Vulgaris After the Use of a Combination of Anti-Acne CreamAcne VulgarisNCT04118296Sukma Skin Treatment150
尚未招募
不适用
A study to compare efficacy of itraconazole capsules and super bioavailable itraconazole capsules in treatment of ringworm.CTRI/2022/04/042183Scarlet Clinic
尚未招募
4 期
To check oil reduction for MIC Beads 100CTRI/2024/05/066798BIOWEG UG
已完成
不适用
Efficacy and Tolerance of a Derivative of Salicylic Acid and 5% Benzoyl Peroxide in Facial Acne VulgarisAcne VulgarisNCT00624676Cosmetique Active International80
Unknown
不适用
Evaluate the Efficacy and Safety of Intense Pulsed Light Filters Combined With Oral Medication in the Treatment of AcneAcne VulgarisNCT04433143Gang Wang60